CClinicalTrials.gg
CompletedNCT03400709Updated Jan 17, 2018

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

An interventional study of N Acetylcysteine and Placebo Oral Tablet in Cisplatin Adverse Reaction and Hearing Loss Ototoxic, sponsored by Hospital San Juan de Dios, Santiago. Completed at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by Hospital San Juan de Dios, Santiago · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients. Early diagnosis is essential because it would allow the appropriate implementation of strategies to reduce its effect. Among these N-acetylcysteine, an antioxidant agent that has shown otoprotective effect. Study design. Randomized, parallel design and placebo controlled clinical trial. Methods. Patients with head and neck cancer who require treatment with cisplatin were enrolled in 2 branches: a control group that receives a placebo and experimental group that receives the drug. High-frequency audiometries (6 - 16 KHz) are performed before, during and after the treatment finalization.

02

Conditions studied

  • Cisplatin Adverse Reaction
  • Hearing Loss Ototoxic

Keywords

  • Cisplatin
  • Ototoxicity
  • N-acetylcisteine
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults Patients with Head and Neck Squamous Cell carcinoma requiring Chemoradiotherapy including Cisplatin.

Exclusion criteria

Exclusion Criteria:

  • Conductive Hearing Loss
  • SNHL with >= 40db PTA
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    N-acetylcisteine group

    Drug: N Acetylcysteine

  • Placebo comparator
    Control group

    Drug: Placebo Oral Tablet

Interventions

  • DrugN Acetylcysteine

    Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.

  • DrugPlacebo Oral Tablet

    Placebo treatment

05

What researchers measure

Primary outcomes

  1. Hearing threshold

    High frequencies pure tone average

    Time frame: Baseline.

  2. Hearing threshold

    High frequencies pure tone average

    Time frame: up to 4th week of chemoradiotherapy

  3. Hearing threshold

    High frequencies pure tone average

    Time frame: through study completion, an average of 3 months

06

Study locations

1 site
  • Daniel Munoz
    Santiago, Metropolitana 7160166, Chile
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03400709
Lead sponsor
Hospital San Juan de Dios, Santiago
Responsible party
Daniel Munoz MD, MSc. (Otolaryngologist, Clinical Epidemiologist., Hospital San Juan de Dios, Santiago) — Principal investigator
First posted
Jan 17, 2018
Start date
Nov 2015
Primary completion
Jun 2017
Completion
Nov 2017
Last update
Jan 17, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion